Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa — REIN-PD  

Impulse Control Disorder Clinical Trial

Official title: The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement Therapy

Status Completed

Clinical Trial Summary

The purpose of this study is to see whether the ICDs(Impulse Control Disorder) are improved and neuropsychiatric traits related to ICD are changed or not when switching dopamine agonist to levodopa/carbidopa in patients with Parkinson's disease who have been treated with dopaminergic medications.

Clinical Trial Description

• PRIMARY OBJECTIVE To evaluate the improvement of mMIDI(modified version of Minnesota Impulsive Disorders Interview,Korean version) score from the baseline to 12 weeks or LOCF(Last Observation Carried Forward)

• SECONDARY OBJECTIVE i) To evaluate the improvement of neuropsychiatric profiles from the baseline to 12 weeks or LOCF ii) To evaluate the improvement of UPDRS(Unified Parkinson's Disease Rating Scale)Score from the baseline to 12 weeks or LOCF ;

Related Conditions & MeSH terms

• Impulse Control Disorder

• NCT number: NCT01683253
• Study type: Interventional
• Source: Sandoz
• Status: Completed
• Phase: Phase 4
• Start date: November 2012
• Completion date: December 2014